- Price
- $190.95
- Day
- -3.04%
- Mkt Cap
- $40.60B
- 52W Range
- $42.18 – $224.31
- Volume
- 5.94M
- Beta
- 1.41
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Engineers Gate Manager LP increased its stake in shares of Revolution Medicines, Inc. (NASDAQ: RVMD) by 144.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,380 shares of the company's stock after purchasing an additional 4,356 shares during the quarter.
Read full article
Axsome Therapeutics is generating rapid revenue growth through its expanding portfolio of commercialized central nervous system treatments. Revolution Medicines is advancing a high-potential pipeline of RAS(ON) inhibitors aimed at treating some of the most difficult cancers.
Read full article
Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) insider Stephen Kelsey sold 92,531 shares of the stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $202.36, for a total transaction of $18,724,573.16. Following the transaction, the insider directly owned 291,876 shares of the company's stock, valued at
Read full article
Revolution Medicines validated its approach to treating certain cancers with a recent regulatory approval. The company's new medicine might become the top-prescribed treatment in its indication.
Read full article
Concurrent Investment Advisors LLC bought a new stake in Revolution Medicines, Inc. (NASDAQ: RVMD) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 2,534 shares of the company's stock, valued at approximately $475,000. Several other large investors have also modified their
Read full article
REDWOOD CITY, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to RASONQUE (daraxonrasib), the company's RAS(ON) multi-selective inhibitor, for treatment-naïve metastatic pancreatic adenocarcinoma (PDAC) in combination with gemcitabine and nab-paclitaxel (GnP), a multiagent chemotherapy regimen widely used in treating patients with PDAC. RASONQUE was recently approved by the U.S. FDA for the treatment of adult patients with metastatic PDAC who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
Read full article
Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) Director Lorence Kim sold 17,090 shares of the firm's stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $209.82, for a total transaction of $3,585,823.80. The sale was disclosed in a filing with the SEC, which is accessible through
Read full article
Amgen maintains a massive global footprint and generated over $8.1 billion in free cash flow during its latest fiscal year. Revolution Medicines is a clinical-stage oncology specialist focused on high-stakes breakthrough therapies for RAS-addicted cancers.
Read full article
Arizona State Retirement System boosted its holdings in shares of Revolution Medicines, Inc. (NASDAQ: RVMD) by 17.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 46,382 shares of the company's stock after buying an additional 6,986 shares during the quarter. Arizona State
Read full article
Revolution Medicines NASDAQ: RVMD just landed one of the biggest wins in oncology this year, and the stock barely blinked. On Aug. 26, the FDA approved RASONQUE (daraxonrasib), the first broad RAS-targeted therapy for metastatic pancreatic cancer.
Read full article
Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock?
Read full article
REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that The New England Journal of Medicine (NEJM) has published a report describing data from the Phase 1/2 clinical trial evaluating RASONQUE (daraxonrasib), an oral, RAS(ON) multi-selective inhibitor, in patients with previously treated advanced RAS mutant non-small cell lung cancer (NSCLC).
Read full article